Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chun-Jen Liu

Showing results (331-340 of 367) with videos related to

Pageof 37
Sort By:
Clinical and Molecular Hepatology|July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut|January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International|March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International|January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in TaiwanChen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
The American Journal of Gastroenterology|March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
Pageof 37

Showing results (331-340 of 367) with videos related to

Sort By:
Pageof 37
Clinical and Molecular Hepatology|July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut|January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International|March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International|January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in TaiwanChen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
The American Journal of Gastroenterology|March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
Pageof 37